Adrenocortical carcinoma: Review and update

Advances in Anatomic Pathology

Volumn 21, Issue 3, 2014, Pages 151-159

  Erickson, Lori A ^a   Rivera, Michael ^a   Zhang, Jun ^a  

^a MAYO CLINIC   (United States)

Author keywords

adrenal; adrenocortical; carcinoma; IGF2; myxoid; oncocytic; TP53; catenin

Indexed keywords

BETA CATENIN; MICRORNA; SOMATOMEDIN; TRANSCRIPTOME; WNT PROTEIN; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ALGORITHM; BECKWITH WIEDEMANN SYNDROME; CANCER PROGNOSIS; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME ABERRATION; EPIGENETICS; FAMILIAL CANCER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; MYXOID ADRENOCORTICAL CARCINOMA; ONCOCYTIC ADRENOCORTICAL TUMOR; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ADRENAL CORTEX TUMOR; CANCER GRADING; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; HUMANS; NEOPLASM GRADING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898406269     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000019     Document Type: Review

References (98)

1. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993;72:3145-3155.
2. Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol. 1989; 141:257-260.
3. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996;119:161-170.
4. Else T, Williams AR, Sabolch A, et al. Adjuvant therapies, patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;99:455-461.
5. Erickson LA, Jin L, Sebo TJ, et al. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol. 2001;12:429-435.
6. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891-899.
7. Didolkar MS, Bescher RA, Elias EG, et al. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer. 1981;47:2153-2161.
8. Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2013;386:67-84.
9. Erickson LA, Lloyd RV, Hartman R, et al. Cystic adrenal neoplasms. Cancer. 2004;101:1537-1544.
10. Erickson LA, Jin L, Sebo TJ, et al. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol. 2001;12:429-435.
11. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26: 1612-1619.
12. Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37:1433-1440.
13. Kjellman M, Kallioniemi OP, Karhu R, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996;56:4219-4223.
14. Canter DJ, Mallin K, Uzzo RG, et al. Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Can J Urol. 2013;20:6915-6921.
15. Gandour MJ, Grizzle WE. A small adrenocortical carcinoma with aggressive behavior. An evaluation of criteria for malignancy. Arch Pathol Lab Med. 1986;110:1076-1079.
16. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163-169.
17. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202-206.
18. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009; 40:757-768.
19. van Slooten H, Schaberg A, Smeenk D, et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985;55:766-773.
20. van't Sant HP, Bouvy ND, Kazemier G, et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology. 2007;51: 239-245.
21. Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535-543.
22. Blanes A, Diaz-Cano SJ. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007;127:398-408.
23. Wachenfeld C, Beuschlein F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol. 2001;145:335-341.
24. Schmitt A, Saremaslani P, Schmid S, et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology. 2006;49:298-307.
25. Soon PS, Gill AJ, Benn DE, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16:573-583.
26. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008; 55:49-55.
27. Duregon E, Volante M, Giorcelli J, et al. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol. 2013;44:822-828.
28. Gupta D, Shidham V, Holden J, et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol. 2001;9: 215-221.
29. Arola J, Salmenkivi K, Liu J, et al. p53 and Ki67 in adrenocortical tumors. Endocr Res. 2000;26:861-865.
30. Nakazumi H, Sasano H, Iino K, et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol. 1998;11:1165-1170.
31. Duregon E, Volante M, Cappia S, et al. Oncocytic adrenocortical tumors: diagnostic algorithm and mitochondrial DNA profile in 27 cases. Am J Surg Pathol. 2011;35:1882-1893.
32. Papotti M, Libe R, Duregon E, et al. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Hormones Cancer. 2011;2:333-340.
33. McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg. 2013;48:1025-1031.
34. Federici S, Galli G, Ceccarelli PL, et al. Adrenocortical tumors in children: a report of 12 cases. Eur J Pediatr Surg. 1994;4: 21-25.
35. Chen QL, Su Z, Li YH, et al. Clinical characteristics of adrenocortical tumors in children. J Pediatr Endocrinol Metab. 2011;24(7-8):535-541.
36. Ciftci AO, Senocak ME, Tanyel FC, et al. Adrenocortical tumors in children. J Pediatr Surg. 2001;36:549-554.
37. Hanna AM, Pham TH, Askegard-Giesmann JR, et al. Outcome of adrenocortical tumors in children. J Pediatr Surg. 2008;43:843-849.
38. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22:838-845.
39. Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27:867-881.
40. Magro G, Esposito G, Cecchetto G, et al. Pediatric adrenocortical tumors: morphological diagnostic criteria and immunohistochemical expression of matrix metalloproteinase type 2 and human leucocyte-associated antigen (HLA) class II antigens. Results from the Italian Pediatric Rare Tumor (TREP) Study project. Hum Pathol. 2012;43:31-39.
41. Mearini L, Del Sordo R, Costantini E, et al. Adrenal oncocytic neoplasm: a systematic review. Urol Int. 2013;91: 125-133.
42. Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol. 2002; 15:973-978.
43. Lin BT, Bonsib SM, Mierau GW, et al. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol. 1998;22:603-614.
44. Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol. 2004;12:231-243.
45. Bisceglia M, Ben-Dor D, Pasquinelli G. Oncocytic adrenocortical tumors. Pathol Case Rev. 2005;10:228-242.
46. Wong DD, Spagnolo DV, Bisceglia M, et al. Oncocytic adrenocortical neoplasms-A clinicopathologic study of 13 new cases emphasizing the importance of their recognition. Hum Pathol. 2011;42:489-499.
47. Forsthoefel KF. Myxoid adrenal cortical carcinoma. A case report with differential diagnostic considerations. Arch Pathol Lab Med. 1994;118:1151-1153.
48. Gurzu S, Szentirmay Z, Bara T, et al. Myxoid variant of adrenocortical carcinoma: a report of two illustrative cases and a brief review of the literature. Pathology. 2014;46:83-85.
49. Hsieh MS, Chen JH, Lin LW. Myxoid adrenal cortical carcinoma presenting as primary hyperaldosteronism: case report and review of the literature. Int J Surg Pathol. 2011; 19:803-807.
50. Izumi M, Serizawa H, Iwaya K, et al. A case of myxoid adrenocortical carcinoma with extensive lipomatous metaplasia. Arch Pathol Lab Med. 2003;127:227-230.
51. Karim RZ, Wills EJ, McCarthy SW, et al. Myxoid variant of adrenocortical carcinoma: report of a unique case. Pathol Int. 2006;56:89-94.
52. Papotti M, Volante M, Duregon E, et al. Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. Am J Surg Pathol. 2010;34:973-983.
53. Suresh B, Kishore TA, Albert AS, et al. Myxoid adrenal cortical carcinoma-A rare variant of adrenocortical carcinoma. Indian J Med Sci. 2005;59:505-507.
54. Tang CK, Harriman BB, Toker C. Myxoid adrenal cortical carcinoma: a light and electron microscopic study. Arch Pathol Lab Med. 1979;103:635-638.
55. Weissferdt A, Phan A, Suster S, et al. Myxoid adrenocortical carcinoma: a clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol. 2013;139:780-786.
56. Brown FM, Gaffey TA, Wold LE, et al. Myxoid neoplasms of the adrenal cortex: a rare histologic variant. Am J Surg Pathol. 2000;24:396-401.
57. Bollito ER, Papotti M, Porpiglia F, et al. Myxoid adrenocortical adenoma with a pseudoglandular pattern. Virchows Arch. 2004;445:414-418.
58. Renshaw AA, Granter SR. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11: 1160-1164.
59. Loy TS, Phillips RW, Linder CL. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med. 2002;126:170-172.
60. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
61. Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol. 2010;34:423-432.
62. Bertherat J, Groussin L, Bertagna X. Mechanisms of disease: adrenocortical tumors-molecular advances and clinical perspectives. Nature clinical practice. Endocrinol Metab. 2006; 2:632-641.
63. Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab. 2002;87:3467-3474.
64. Barreau O, de Reynies A, Wilmot-Roussel H, et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. J Clin Endocrinol Metab. 2012;97:E301-E311.
65. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009;15:668-676.
66. Assie G, Guillaud-Bataille M, Ragazzon B, et al. The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends Endocrinol Metab. 2010;21:325-334.
67. Ragazzon B, Assie G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer. 2011; 18:R15-R27.
68. Ragazzon B, Libe R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70: 8276-8281.
69. de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90:1819-1829.
70. de Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27:1108-1115.
71. Durand J, Lampron A, Mazzuco TL, et al. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. J Clin Endocrinol Metab. 2011;96:E1206-E1211.
72. Fernandez-Ranvier GG, Weng J, Yeh RF, et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg. 2008;143:841-846; discussion 46.
73. Song R, Duarte TL, Almeida GM, et al. Cytotoxicity and gene expression profiling of two hydroxylated polybrominated diphenyl ethers in human H295R adrenocortical carcinoma cells. Toxicol Lett. 2009;185:23-31.
74. Gicquel C, Le Bouc Y. Molecular markers for malignancy in adrenocortical tumors. Horm Res. 1997;47(4-6):269-272.
75. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab. 1997;82: 2559-2565.
76. Gao ZH, Suppola S, Liu J, et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J Clin Endocrinol Metab. 2002;87: 1170-1176.
77. Rosati R, Cerrato F, Doghman M, et al. High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet Cytogenet. 2008;186:19-24.
78. Ribeiro TC, Latronico AC. Insulin-like growth factor system on adrenocortical tumorigenesis. Mol Cell Endocrinol. 2012; 351:96-100.
79. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162:521-531.
80. Choong SS, Latiff ZA, Mohamed M, et al. Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations. Clin Genet. 2012;82: 564-568.
81. Custodio G, Parise GA, Kiesel Filho N, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2013;31:2619-2626.
82. Raymond VM, Else T, Everett JN, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:E119-E125.
83. Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol Cell Endocrinol. 2012;351:52-57.
84. Libe R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007; 13:844-850.
85. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622-7627.
86. Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol. 2012;181:1017-1033.
87. Patterson EE, Holloway AK, Weng J, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2011;117:1630-1639.
88. Caramuta S, Lee L, Ozata DM, et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013;20:551-564.
89. Ozata DM, Caramuta S, Velazquez-Fernandez D, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer. 2011;18:643-655.
90. Singh P, Soon PS, Feige JJ, et al. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol. 2012;351: 118-128.
91. Tombol Z, Szabo PM, Molnar V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: micro- RNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009;16:895-906.
92. Zsippai A, Szabo PM, Szabo DR, et al. In silico analysis of pathways affected by differentially expressed microRNAs in adrenocortical tumors. J Endocrinol Invest. 2013;36:1011-1019.
93. Wang C, Sun Y, Wu H, et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64:567-576.
94. Fonseca AL, Kugelberg J, Starker LF, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer. 2012;51:949-960.
95. Barreau O, Assie G, Wilmot-Roussel H, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 2013;98:E174-E184.
96. Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery. 2006; 140:914-920; discussion 19-20.
97. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130-3136.
98. De Martino MC, Al Ghuzlan A, Aubert S, et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab. 2013;98: 4080-4088.